DrugPatentWatch Database Preview
KINEVAC Drug Profile
see a sample report or, see our see our flat-rate plans
When do Kinevac patents expire, and when can generic versions of Kinevac launch?
This drug has ten patent family members in eight countries.
The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sincalide profile page.
Summary for KINEVAC
| International Patents: | 10 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 32 |
| Clinical Trials: | 1 |
| Patent Applications: | 302 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KINEVAC |
| DailyMed Link: | KINEVAC at DailyMed |
Pharmacology for KINEVAC
| Ingredient-type | Cholecystokinin |
| Drug Class | Cholecystokinin Analog |
Synonyms for KINEVAC
| (3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,2 |
| (3S)-3-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1S |
| (3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl |
| (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-(methylthio)-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino] |
| (3S)-3-azanyl-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-azanyl-1-oxidanylidene-3-phenyl-propan-2-yl]amino]-4-oxidanyl-1,4-bis(oxidanylidene)butan-2-yl]amino]-4-methylsulfanyl-1-oxidanylidene-butan-2-yl]amino |
| (Tyr[SO3H]27)Cholecystokinin fragment 26-33 Amide |
| [125I]CCK-8 |
| 1-De(5-oxo-L-proline)-2-de-L-glutamine-5-L-methioninecaerulein |
| 126S323 |
| 25126-32-3 |
| 25345-10-2 |
| 3-amino-4-[[1-[[1-[[2-[[1-[[1-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-hydroxy-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsul |
| 89911-55-7 |
| 9038-72-6 |
| 91921-74-3 |
| A817659 |
| AC1L1OGF |
| AKOS015896031 |
| AKOS016340423 |
| AM021026 |
| Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 |
| Asp-Tyr[SO3 H]-Met-Gly-Trp-Met -Asp-Phe-NH2 |
| Asp-Tyr[SO3 H]-Met-Gly-Trp-Met-Asp-Phe-NH2 |
| BDBM21147 |
| C49H62N10O16S3 |
| Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-5-L-methionine- |
| CAS-25126-32-3 |
| CCK 26-33, sulfated |
| CCK C-terminal octapeptide |
| CCK Octapeptide, sulfated |
| CCK-8 |
| CCK-8 (sulphated) |
| CCK-8, sulfated |
| CCK-8(SO3) |
| CHEBI:135946 |
| CHEMBL1121 |
| cholecystokinin 8 |
| cholecystokinin C-terminal octapeptide |
| cholecystokinin fragment 26-33 amide (sulphated) |
| Cholecystokinin octapeptide |
| Cholecystokinin Octapeptide, sulfated |
| Cholecystokinin-8 |
| Cholecystokinin-pancreozymin |
| CS-042 |
| CS-5963 |
| D05845 |
| D09ZAX |
| D0I8AF |
| D0TL7L |
| DB09142 |
| DR003692 |
| DSSTox_CID_28543 |
| DSSTox_GSID_48617 |
| DSSTox_RID_82815 |
| DTXSID7048617 |
| EINECS 246-639-0 |
| FT-0630515 |
| GTPL864 |
| H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 |
| Human CCK-8 |
| HY-P0093 |
| I06-1840 |
| IZTQOLKUZKXIRV-YRVFCXMDSA-N |
| Kinevac (TN) |
| L-alpha-Aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide |
| L-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide hydrogen sulfate (ester) |
| LS-53094 |
| M03GIQ7Z6P |
| MFCD00079849 |
| MolPort-006-124-517 |
| NCGC00167273-01 |
| NCGC00183278-01 |
| NCGC00183363-01 |
| O411 |
| Pancreozymin |
| Pancreozymin C-terminal octapeptide |
| SC-47569 |
| SCHEMBL122365 |
| SCHEMBL1425223 |
| Sincalida |
| Sincalida [INN-Spanish] |
| Sincalide |
| Sincalide (Kinevac) |
| Sincalide (USP/INN) |
| Sincalide [USAN:BAN:INN] |
| Sincalide [USAN:USP:INN:BAN] |
| Sincalidum |
| Sincalidum [INN-Latin] |
| SQ 19844 |
| SQ-19844 |
| Syncalide |
| Tox21_112955 |
| Tox21_113481 |
| UNII-M03GIQ7Z6P |
US Patents and Regulatory Information for KINEVAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | KINEVAC | sincalide | INJECTABLE;INJECTION | 017697-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for KINEVAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | KINEVAC | sincalide | INJECTABLE;INJECTION | 017697-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for KINEVAC
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1631305 | ➤ Try a Free Trial |
| Canada | 2503982 | ➤ Try a Free Trial |
| Australia | 2003304382 | ➤ Try a Free Trial |
| Japan | 4751993 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
